Posted by Michael Wonder on 19 Jul 2026
US FDA accepts Bristol Myers Squibb's new drug application for mezigdomide in patients with relapsed or refractory multiple myeloma
13 July 2026 - Bristol Myers Squibb today announced that the US FDA has accepted a new drug application for mezigdomide in combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma.
The FDA has granted a PDUFA date of 13 May 2027 for this indication.
